Treatment of Chronic RhinoSinusitis (Inflamation of Sinusis and Nasal cavity) with Unani medicine Itrifal Kishneezi

Clinical Validation of Unani Pharmacopoeial Formulation Itrifal Kishneezi in Nazla Muzmin (Chronic RhinoSinusitis)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/017945

Enrollment

240

Registered

2019-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified

Interventions

Intervention1: Itrifal Kishneezi: 10 gm Orally twice daily to be taken with water for 4 weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex of age 18-65 years 2. Patients with Sino-Nasal Outcome Test (SNOT) > 7 3. Patients clinically diagnosed of sinusitis of duration > 12 weeks with radiological changes.

Exclusion criteria

Exclusion criteria: 1. Patients of sinusitis with epistaxis, hypertension shall be excluded from the study 2. Patient having any growth in the nose like nasal polyps etc. 3. Patients with co-morbidity requiring long term treatment. 4. Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Nazla Muzmin (Chronic RhinoSinusitis)Timepoint: 04 Weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026